Update shared on 04 Dec 2025
Analysts have slightly refined their assumptions for Hera, leading to a modestly adjusted price target that still reflects stable fair value of 4.35. Updated discount rate, revenue growth, profit margin, and future P/E inputs support a largely unchanged long term outlook.
Valuation Changes
- Fair Value Estimate remains unchanged at €4.35, indicating no reassessment of Hera's intrinsic value.
- The discount rate is effectively flat at 8.97 percent, suggesting a stable view of Hera's risk profile and cost of capital.
- Revenue growth has been revised only marginally and remains at approximately negative 1.13 percent, signaling a largely unchanged expectation of slight top line contraction.
- The net profit margin has been adjusted upward by an immaterial amount, holding close to 3.79 percent and implying a steady profitability outlook.
- The future P/E ratio is effectively steady at about 17.11x, reflecting a consistent view of Hera's forward earnings multiple.
Have other thoughts on Hera?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.